These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatment Outcomes. Regier PS; Kampman KM; Childress AR Handb Exp Pharmacol; 2020; 258():299-322. PubMed ID: 32193666 [TBL] [Abstract][Full Text] [Related]
7. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. Kishi T; Matsuda Y; Iwata N; Correll CU J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatments for methamphetamine addiction: current status and future directions. Ballester J; Valentine G; Sofuoglu M Expert Rev Clin Pharmacol; 2017 Mar; 10(3):305-314. PubMed ID: 27927042 [TBL] [Abstract][Full Text] [Related]
9. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Sofuoglu M Addiction; 2010 Jan; 105(1):38-48. PubMed ID: 20078461 [TBL] [Abstract][Full Text] [Related]
10. Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders. Amin-Esmaeili M; Susukida R; Johnson RM; Farokhnia M; Crum RM; Thrul J; Mojtabai R Drug Alcohol Depend; 2021 Sep; 226():108904. PubMed ID: 34304121 [TBL] [Abstract][Full Text] [Related]
11. Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine. Stoops WW Exp Clin Psychopharmacol; 2006 Nov; 14(4):413-21. PubMed ID: 17115868 [TBL] [Abstract][Full Text] [Related]
12. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Kiluk BD; Carroll KM; Duhig A; Falk DE; Kampman K; Lai S; Litten RZ; McCann DJ; Montoya ID; Preston KL; Skolnick P; Weisner C; Woody G; Chandler R; Detke MJ; Dunn K; Dworkin RH; Fertig J; Gewandter J; Moeller FG; Ramey T; Ryan M; Silverman K; Strain EC Drug Alcohol Depend; 2016 Jan; 158():1-7. PubMed ID: 26652899 [TBL] [Abstract][Full Text] [Related]
13. Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction. Jing L; Li JX Eur J Pharmacol; 2015 Aug; 761():345-52. PubMed ID: 26092759 [TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. Wu EQ; Hodgkins P; Ben-Hamadi R; Setyawan J; Xie J; Sikirica V; Du EX; Yan SY; Erder MH CNS Drugs; 2012 Jul; 26(7):581-600. PubMed ID: 22712698 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Haile CN; Kosten TR; Kosten TA Am J Drug Alcohol Abuse; 2009; 35(3):161-77. PubMed ID: 19462300 [TBL] [Abstract][Full Text] [Related]
16. Current concepts in pharmacotherapy of substance abuse. Gottschalk PC; Jacobsen LK; Kosten TR Curr Psychiatry Rep; 1999 Dec; 1(2):172-8. PubMed ID: 11122921 [TBL] [Abstract][Full Text] [Related]
17. Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date. Lee MR; Leggio L CNS Drugs; 2014 Feb; 28(2):107-19. PubMed ID: 24497006 [TBL] [Abstract][Full Text] [Related]
18. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Ciccarone D Prim Care; 2011 Mar; 38(1):41-58. PubMed ID: 21356420 [TBL] [Abstract][Full Text] [Related]
19. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Herin DV; Rush CR; Grabowski J Ann N Y Acad Sci; 2010 Feb; 1187():76-100. PubMed ID: 20201847 [TBL] [Abstract][Full Text] [Related]